1/1
3 files

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

media
posted on 27.08.2021, 08:41 by Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Hidesaku Asakura, Teiichi Yamane, Yukako Ogi, Kaori Ochiai, Daisuke Nakayama

Provide enhanced digital features for this article

This Figshare page contains a Slide deck and Video Abstract. If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact adisrapidplus@springer.com.

The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.

Other enhanced features include, but are not limited to:
• Slide decks
• Videos and animations
• Audio abstracts
• Audio slides

Funding

Nippon Boehringer Ingelheim Co., Ltd.

History